To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients

ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) Clinical Trial

Official title:
A Research Study to Describe the Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS). An Assessment of Two Case Studies

Status Completed

Clinical Trial Summary

This protocol is intended to formally collect data on the treatment of aHUS with eculizumab in Japanese patients.

Clinical Trial Description

n/a

Study Design

Time Perspective: Retrospective

Related Conditions & MeSH terms

ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)
Azotemia
Hemolysis
Hemolytic-Uremic Syndrome

Clinical Trial Details

NCT number	NCT01755429
Study type	Observational
Source	Alexion Pharmaceuticals
Contact
Status	Completed
Phase	N/A
Start date	May 2012
Completion date	July 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01757431` - The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)	Phase 2
Not yet recruiting	`NCT06312644` - Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Completed	`NCT02949128` - Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)	Phase 3
Completed	`NCT03131219` - Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)	Phase 3
Completed	`NCT01770951` - A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)